<DOC>
	<DOCNO>NCT01426087</DOCNO>
	<brief_summary>The main complication cirrhosis ascites , esophageal varix hepatic encephalopathy . About 30 % 70 % patient cirrhosis occur esophageal varix , common complication ascites . Somatostatin use treat esophageal long time , otherwise could aslo prevent ascites . In study , investigator explore effect somatostatin post-endoscopic portal hemodynamic cirrhotic patient esophageal gastric varix .</brief_summary>
	<brief_title>Effects Somatostatin Post-endoscopic Portal Hemodynamic Cirrhotic Patients With Esophageal Gastric Varices</brief_title>
	<detailed_description>126 patient enrol study , 63 subject randomize group A group B . Group A : endoscopic therapy somatostatin treatment . Group B : endoscopic therapy .</detailed_description>
	<mesh_term>Varicose Veins</mesh_term>
	<mesh_term>Esophageal Gastric Varices</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Cirrhosis esophageal gastric varix need endoscopic therapy Age 1875 year Informed write consent Use vasoactive drug 24 hour endoscopic treatment Use Bblocker within 1 week Previous surgical endoscopic treatment esophageal gastric varix Hepatic encephalopathy , comatose status disease could accept endoscopic therapy Gastrorenal vein shunt Severe hepatic hydrothorax Hepatocellular carcinoma portal vein thrombosis Severe coagulation disorder Severe active bacteria infection Severe cardiovascular disease , include history acute myocardial infarction , heart block , heart failure Severe renal function insufficiency （Calculated Creatinine Clearance Rate ( Ccr ) ＜30ml/min） Severe comorbidity would affect shortterm prognosis Pregnancy lactation Allergy ingredient trial medication Medical psychological condition would permit patient complete study sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>